BioNTech SE (BNTX)
100.60
+1.85
(+1.87%)
USD |
NASDAQ |
May 31, 16:00
100.51
-0.09
(-0.09%)
After-Hours: 20:00
BioNTech SG&A Expense (Quarterly): 144.03M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 144.03M |
December 31, 2023 | 160.89M |
September 30, 2023 | 164.19M |
June 30, 2023 | 144.81M |
March 31, 2023 | 133.18M |
December 31, 2022 | 148.27M |
September 30, 2022 | 150.30M |
June 30, 2022 | 153.92M |
March 31, 2022 | 117.93M |
December 31, 2021 | 159.89M |
September 30, 2021 | 92.79M |
June 30, 2021 | 73.64M |
Date | Value |
---|---|
March 31, 2021 | 57.36M |
December 31, 2020 | 55.44M |
September 30, 2020 | 31.11M |
June 30, 2020 | 22.25M |
March 31, 2020 | 17.99M |
December 31, 2019 | 7.653M |
September 30, 2019 | 12.51M |
June 30, 2019 | 15.44M |
March 31, 2019 | 10.07M |
December 31, 2018 | 10.11M |
September 30, 2018 | 8.520M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
7.653M
Minimum
Dec 2019
164.19M
Maximum
Sep 2023
93.18M
Average
105.36M
Median
SG&A Expense (Quarterly) Benchmarks
Pfizer Inc | 3.495B |
Moderna Inc | 274.00M |
GSK PLC | 2.647B |
NuCana PLC | 2.005M |
Autolus Therapeutics PLC | 18.18M |